Clinical Trial

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Study acronym: EPIC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Protocol Amendment History 3 changes
minor Completion moved earlier: 2029-07-31 -> 2029-01-29 2026-07-07
minor Completion pushed: 2028-12-11 -> 2029-07-31 2026-06-06
notable Trial sites expanded: 8 -> 12 locations 2026-05-09
Trial Details
NCT Number NCT07217587
Lead Sponsor Janssen Research & Development, LLC
Conditions Myasthenia Gravis
Enrollment 115 participants
Start Date 2026-01-05
Primary Completion 2027-09-28 (estimated)
Study Completion 2029-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-31